The AI Revolution in Cancer:
Grab your musket & don't wait for a silver bullet.
Ask any AI frontier lab leader what AI will do for humanity and "cure cancer" tops every list.
The image is always the same: miracle drugs. That's not how it's actually playing out.
...
From Google to fighting cancer | Othman Laraki (@othman)
What if the cancer center of the future had no walls? And what if AI could help save millions of lives?
In this episode of OncoInfluencer Series by OncoDaily TV, Dr. Gevorg Tamamyan (@GevTamamyan), Editor-in-Chief of OncoDaily and Candidate for @WHO Director-General, sits down with Laraki for a deeply personal conversation about leadership, innovation, and the future of cancer care.
From the alarming gap between scientific advances and everyday clinical practice to the human cost of delayed diagnoses, they explore some of healthcare’s most urgent challenges.
Can virtual cancer clinics bring world-class care to everyone, regardless of where they live? Could AI revolutionize cancer prevention, diagnosis, treatment, and survivorship?
“AI can help us save millions of people from cancer.” — Othman Laraki
A story of family, ambition, and a bold vision to make cancer care faster, smarter, and accessible to all.
Watch the full interview on OncoDaily TV:
youtube.com/watch?v=y0vOe6Sw…
6/ @Tesla, get your act together on the small stuff. You literally made a customer who had trouble imagining buying any other car feel you don't deserve another dollar from them because of a $5 part. I know this ridiculous runaround was not intentional, but you can be intentional about giving agency to your team to avoid stupid outcomes.
5/ I don't think I ever posted about a product I'm pissed off about. It struck me that shitty products are all over the place and I dismiss them and don't get dwell on it. This drove me up the wall BECAUSE of how much I like the car and product. The more loyal and appreciative of a product the more infuriating it is when you're disappointed and feel disrepsected.
4/ Now, after taking the time to go to their service center - an imbecile there takes the position that if it wasn't installed by Tesla, they CAN'T be sure that I didn't damage the part they can see is clearly not damaged but doesn't fit properly.
3/ Next @Tesla had me schedule a service visit because that was the only way to ascertain that it was indeed defective (again, remember $5 part!). They could see the part in photos and it not fitting, but despite tons of AI junk on the app, no human with agency to just fix it.
2/ @Tesla's support chatbot told me there was no warranty or repair path for the rack, pointing to the expired return window. That was a poorly-implemented AI tool - turns out that was incorrect - it's a warranty issue.
1/ I bought a roof rack from @Tesla own shop. The front-right mount doesn't line up with the roof line, so the cover won't clip on properly. A small part. Should have been a small fix.
It is mind-boggling when companies build an amazing product and fuck it up disrespecting customers on ticky-tacky shit.
Getting a @Tesla Y with FSD is the first iPhone-level moment I had with tech in a decade - only to waste hours of my time on a $5 defective roof rack part.
New Phase 3 results shared at this year’s @myESMO mark a pivotal moment for cancer vaccines, bringing new promise for personalized cancer care.
In a new @statnews byline, Parker Institute CEO @DrKarenKnudsen and @Color CEO @othman explore how lessons from BRCA testing can help accelerate cancer vaccine development and expand access for patients.
Read the piece here: statnews.com/2026/10/27/canc…
The opportunities have never been greater. As they grow, so does the social and ethical imperative to remove the barriers between the science and the patients it’s meant for.
Guidelines are dead, long live guidelines. A process that takes years to produce prescriptive recommendations no longer makes sense: cancer is too complex and the deliberation too slow. We need a new model for how consensus on care is formed and propagated. My bet: an AI-driven system that is statistical, handles the real complexity of patients and treatments, and updates as fast as the evidence does. When discoveries land every week, locking access behind years of deliberation is unacceptable.
Payers lose money saving your life down the road. Standard health insurance has zero ROI on your health years from now, because by then you’ll be on someone else’s dime. At Color, we routinely debate health plan CMOs on the merits of mammograms and PSAs, which cost a few hundred dollars. Now imagine hundreds of thousands. Even when access is legislated, the incentives don’t change, and patients die by a thousand cuts. Our bet is that the path runs through patients and employers, who have longer horizons and can go direct, driving the cost down. We all just lived through this with GLP-1s.
Fragmentation breeds middlemen and breaks the experience. A cancer vaccine isn’t a drug in a vial. To a patient it’s a multi-year chain: tumor sampling and sequencing, vaccine design, manufacturing, nine doses over a year, and years of monitoring. If every link belongs to a separate provider with its own contracts and headaches, middlemen dominate the cost and friction keeps a life-saving therapy out of reach for most.